Johnson & Johnson (JNJ): Among the Best Performing Dow Stocks So Far in 2025
We recently published a list of 11 Best Performing Dow Stocks So Far in 2025. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best performing ...
Hosted on MSN1mon
Nose spray to treat depression? FDA approves first-of-its-kind medicine
NEW YORK (WPIX) – The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday. Spravato is a first-of-its-kind medication to ...
Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around?
Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar ...
NBC Connecticut1mon
FDA approves Johnson & Johnson's nasal spray for depression as standalone treatment
The Food and Drug Administration approved Johnson & Johnson's nasal spray ... first-ever standalone therapy for treatment-resistant depression, which is when trying at least two standard ...
Benzinga.com1mon
Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?
Johnson & Johnson’s Spravato gains FDA approval for standalone depression treatment ahead of Q4 earnings. JNJ stock shows short-term bullish signals, but long-term trends remain bearish ahead of ...
Can AI Unlock New Treatment Possibilities For Inflammatory Bowel Disease? How Johnson & Johnson Is Leading The Way
Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...